abs

학술발표회초록보기

Inquiry on Abstract abstract@kcsnet.or.kr

Inquiry on Payment member@kcsnet.or.kr

현재 가능한 작업은 아래와 같습니다.
  • 03월 01일 23시 이후 : 초록수정 불가능, 일정확인 및 검색만 가능

129th General Meeting of Korean Chemical Society & Exposition Mapping the Degradable Kinome Using PROTACs

Submission Date :
3 / 17 / 2022 , 10 : 06 : 19
Abstract Number :
129031730806
Presenting Type:
Symposium
Presenting Area :
Medicinal Chemistry - The Cutting Edge of Medicinal Chemistry
Authors :
Taebo Sim
Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Korea
Assigned Code :
MEDI1-3 Assigend Code Guideline
Presenting Time :
THU, 16 : 40
Targeted protein degradation (TPD) such as PROTAC, AUTAC, and LYTAC is a promising and emerging therapeutic modality. Targeted protein degradation (TPD) adopting small molecule ligands utilizes ubiquitin proteasome system (UPS) or autophagy lysosomal pathway (ALP). Overactivated protein kinases caused by mutations cause various diseases such as cancer and small molecule kinase inhibitors have intensively been discovered for targeted therapy. Despite the increasing number of small molecule kinase inhibitors approved or in clinical investigations, only 7% of the human kinome has been therapeutically explored. Furthermore, despite the widespread exploration of TPD as a novel pharmacological modality, it still remains hard to predict which protein kinases are tractable and which may prove recalcitrant to this approach. In order to provide useful degrader chemical probes and clinically relevant leads across the kinome, we synthesized a variety of different kinds PROTACs of which warheads are different chemo-types of small molecule kinase inhibitors and chemoproteomic technologies were utilized to annotate the degradable kinome. Our expansive dataset provides novel PROTACs for degrading over 200 kinases. An integrated guideline for designing efficiently novel kinase PROTACs is provided by making the first map that reveals the correlation between chemical structure of the kinase PROTACs and the properties including degradability/selectivity. Moreover, novel AUTACs to degrade effectively disease-associated aggregated proteins will be briefly presented.